Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432.

Academic Article


  • We report on 348 patients ≥ 70 years (median age 78 years) with acute myeloid leukemia (>50% with secondary AML) randomized to receive either 600 mg or 300 mg of tipifarnib orally twice daily on days 1-21 or days 1-7 and 15-21, repeated every 28 days (4 treatment regimens). Responses were seen in all regimens, with overall response rate (CR + CRi + PR) highest (20%) among patients receiving tipifarnib 300 mg twice daily on days 1-21. Toxicities were acceptable. Unless predictors of response to tipifarnib are identified, further study as a single agent in this population is unwarranted.
  • Authors

    Published In

  • Leukemia Research  Journal
  • Keywords

  • Acute myeloid leukemia, Farnesyltransferase inhibitor, Older, Tipifarnib, Untreated, Administration, Oral, Aged, Aged, 80 and over, Drug Administration Schedule, Farnesyltranstransferase, Female, Humans, Leukemia, Myeloid, Acute, Male, Quinolones, Remission Induction, Survival Rate, Treatment Outcome
  • Digital Object Identifier (doi)

    Author List

  • Erba HP; Othus M; Walter RB; Kirschbaum MH; Tallman MS; Larson RA; Slovak ML; Kopecky KJ; Gundacker HM; Appelbaum FR
  • Start Page

  • 329
  • End Page

  • 333
  • Volume

  • 38
  • Issue

  • 3